Human pluripotent-stem-cell-derived organoids for drug discovery and evaluation.

Cell Stem Cell

Department of Surgery, Weill Cornell Medicine, 1300 York Avenue, New York, NY 10065, USA; Center for Genomic Health, Weill Cornell Medicine, 1300 York Avenue, New York, NY 10065, USA. Electronic address:

Published: May 2023

Human pluripotent stem cells (hPSCs) and three-dimensional organoids have ushered in a new era for disease modeling and drug discovery. Over the past decade, significant progress has been in deriving functional organoids from hPSCs, which have been applied to recapitulate disease phenotypes. In addition, these advancements have extended the application of hPSCs and organoids for drug screening and clinical-trial safety evaluations. This review provides an overview of the achievements and challenges in using hPSC-derived organoids to conduct relevant high-throughput, high-contentscreens and drug evaluation. These studies have greatly enhanced our knowledge and toolbox for precision medicine.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10775018PMC
http://dx.doi.org/10.1016/j.stem.2023.04.011DOI Listing

Publication Analysis

Top Keywords

organoids drug
8
drug discovery
8
organoids
5
human pluripotent-stem-cell-derived
4
pluripotent-stem-cell-derived organoids
4
drug
4
discovery evaluation
4
evaluation human
4
human pluripotent
4
pluripotent stem
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!